Top

Published in:

Open Access 01-12-2010 | Research article

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors

Authors: Cristina Patru, Luciana Romao, Pascale Varlet, Laure Coulombel, Eric Raponi, Josette Cadusseau, François Renault-Mihara, Cécile Thirant, Nadine Leonard, Alain Berhneim, Maria Mihalescu-Maingot, Jacques Haiech, Ivan Bièche, Vivaldo Moura-Neto, Catherine Daumas-Duport, Marie-Pierre Junier, Hervé Chneiweiss

Published in: BMC Cancer | Issue 1/2010

Abstract

Background

Tumor initiating cells (TICs) provide a new paradigm for developing original therapeutic strategies.

Methods

We screened for TICs in 47 human adult brain malignant tumors. Cells forming floating spheres in culture, and endowed with all of the features expected from tumor cells with stem-like properties were obtained from glioblastomas, medulloblastoma but not oligodendrogliomas.

Results

A long-term self-renewal capacity was particularly observed for cells of malignant glio-neuronal tumors (MGNTs). Cell sorting, karyotyping and proteomic analysis demonstrated cell stability throughout prolonged passages. Xenografts of fewer than 500 cells in Nude mouse brains induced a progressively growing tumor. CD133, CD15/LeX/Ssea-1, CD34 expressions, or exclusion of Hoechst dye occurred in subsets of cells forming spheres, but was not predictive of their capacity to form secondary spheres or tumors, or to resist high doses of temozolomide.

Conclusions

Our results further highlight the specificity of a subset of high-grade gliomas, MGNT. TICs derived from these tumors represent a new tool to screen for innovative therapies.

Available only for authorised users

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64 (19): 7011-7021. 10.1158/0008-5472.CAN-04-1364.CrossRefPubMed

Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003, 100 (25): 15178-15183. 10.1073/pnas.2036535100.CrossRefPubMedPubMedCentral

Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002, 39 (3): 193-206. 10.1002/glia.10094.CrossRefPubMed

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63 (18): 5821-5828.PubMed

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature. 2004, 432 (7015): 396-401. 10.1038/nature03128.CrossRefPubMed

Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 2004, 23 (58): 9392-9400. 10.1038/sj.onc.1208311.CrossRefPubMed

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100 (7): 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedPubMedCentral

Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 2005, 121 (6): 823-835. 10.1016/j.cell.2005.03.032.CrossRefPubMed

O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445 (7123): 106-110. 10.1038/nature05372.CrossRefPubMed

10.

Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, et al: Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006, 25 (12): 1696-1708. 10.1038/sj.onc.1209327.CrossRefPubMed

11.

Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C: [Gliomas: WHO and Sainte-Anne Hospital classifications]. Ann Pathol. 2000, 20 (5): 413-428.PubMed

12.

Noble M, Dietrich J: The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci. 2004, 27 (3): 148-154. 10.1016/j.tins.2003.12.007.CrossRefPubMed

13.

McConville P, Hambardzumyan D, Moody JB, Leopold WR, Kreger AR, Woolliscroft MJ, Rehemtulla A, Ross BD, Holland EC: Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007, 13 (10): 2897-2904. 10.1158/1078-0432.CCR-06-3058.CrossRefPubMed

14.

Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001, 2 (2): 120-129. 10.1038/35052535.CrossRefPubMed

15.

Ding H, Guha A: Mouse astrocytoma models: embryonic stem cell mediated transgenesis. J Neurooncol. 2001, 53 (3): 289-296. 10.1023/A:1012256230365.CrossRefPubMed

16.

Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, et al: Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 2003, 63 (7): 1589-1595.PubMed

17.

Sharif A, Legendre P, Prevot V, Allet C, Romao L, Studler JM, Chneiweiss H, Junier MP: Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene. 2007, 26 (19): 2695-2706. 10.1038/sj.onc.1210071.CrossRefPubMed

18.

Junier MP: What role(s) for TGFalpha in the central nervous system?. Prog Neurobiol. 2000, 62 (5): 443-473. 10.1016/S0301-0082(00)00017-4.CrossRefPubMed

19.

Dufour C, Cadusseau J, Varlet P, Surena AL, de Faria GP, Dias-Morais A, Auger N, Leonard N, Daudigeos E, Dantas-Barbosa C, et al: Astrocytes Reverted to a Neural Progenitor-like State with Transforming Growth Factor Alpha Are Sensitized to Cancerous Transformation. Stem Cells. 2009, 27 (10): 2373-2382. 10.1002/stem.155.CrossRefPubMedPubMedCentral

20.

Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, Daumas-Duport C: New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery. 2004, 55 (6): 1377-1391. 10.1227/01.NEU.0000143033.36582.40. discussion 1391-1372CrossRefPubMed

21.

Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M: Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res. 2001, 61 (4): 1652-1658.PubMed

22.

Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006, 444 (7120): 761-765. 10.1038/nature05349.CrossRefPubMed

23.

Capela A, Temple S: LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron. 2002, 35 (5): 865-875. 10.1016/S0896-6273(02)00835-8.CrossRefPubMed

24.

Wurmser AE, Nakashima K, Summers RG, Toni N, D'Amour KA, Lie DC, Gage FH: Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature. 2004, 430 (6997): 350-356. 10.1038/nature02604.CrossRefPubMed

25.

Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, Marty S, Nadal L, Pantesco V, Reme T, Hugnot JP, et al: A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 2007, 25 (4): 961-973. 10.1634/stemcells.2006-0352.CrossRefPubMedPubMedCentral

26.

Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K, Sugisaki Y, Onda M, Tsunoda T: Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, alpha-PIX and sorcin. Acta Neuropathol. 2006, 111 (1): 29-38. 10.1007/s00401-005-1085-6.CrossRefPubMed

27.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67 (9): 4010-4015. 10.1158/0008-5472.CAN-06-4180.CrossRefPubMed

28.

Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR, Gillespie GY: CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE. 2008, 3 (11): e3655-10.1371/journal.pone.0003655.CrossRefPubMedPubMedCentral

29.

Son MJ, Woolard K, Nam DH, Lee J, Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009, 4 (5): 440-452. 10.1016/j.stem.2009.03.003.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/66/prepub

Title: CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors
Authors: Cristina Patru
Luciana Romao
Pascale Varlet
Laure Coulombel
Eric Raponi
Josette Cadusseau
François Renault-Mihara
Cécile Thirant
Nadine Leonard
Alain Berhneim
Maria Mihalescu-Maingot
Jacques Haiech
Ivan Bièche
Vivaldo Moura-Neto
Catherine Daumas-Duport
Marie-Pierre Junier
Hervé Chneiweiss
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-10-66

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells

Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker

Differential CARM1 expression in prostate and colorectal cancers

Long-term survival of cancer patients compared to heart failure and stroke: A systematic review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer